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Targeted detection programmes are recommended to identify subjects affected by severe
alpha1-antitrypsin deficiency (AATD). Guidelines are available to address physicians
towards subjects at high risk for AATD. We wanted to investigate the clinical
characteristics of subjects enrolled in the programme, who result as not being affected
by severe AATD; this information is not available in the present literature. We elaborated
data contained in the questionnaires accompanying the samples of 2127 Italian subjects
submitted for AATD detection in a period spanning 11 years (1996–2006).
A total of 588 subjects were eligible to enter this study: PI*MM subjects and subjects with
intermediate AATD, referred for lung disease, were characterised by a relatively young
mean age, and a high proportion (31.2% and 28.6%, respectively) were never smokers. Fifty
percent or more had symptoms of chronic bronchitis, but without obstruction. Only a
minority belonged to most severe GOLD stages. The mean levels of AAT varied as a function
of the presence or absence of airflow obstruction in intermediate AATD subjects, but not in
PI*MM. Individuals enrolled in AATD detection programmes represent an interesting cohort
both for public health and research purposes.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Alpha1-antitrypsin deficiency (AATD) is an inherited condi-
tion characterised by reduced plasma levels of alpha1-
antitrypsin (AAT), and increased risk of developing chronic,Elsevier Ltd. All rights reserved.
2 501004;
o.pv.it (I. Ferrarotti).disabling pulmonary and liver disease.1 The highest pre-
valence of AATD is recorded in northwestern European
countries and in North America, and is linked to the
commonest deficiency variant, referred to as PI*Z
(14q32.1; SERPINA1 gene; 342Glu-Lys).2
Development of national registries for AATD, based on
detection programmes, is considered a critical issue to make
advances in the understanding of the epidemiology and
natural course of the disorder.3 Strategies to detect
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approach used by the majority of European national
detection programmes is referred to as ‘‘targeted detec-
tion’’, and submits individuals at high risk for AATD to
laboratory diagnosis. The ATS/ERS recently published a joint
statement on AATD, indicating that individuals at high risk
fall into the following categories4: individuals with pulmonary emphysema/COPD charac-
terised by early onset, familial clustering, absence of
detectable risk factors, pulmonary bibasilar hyperlu-
cency; individuals with liver disease characterised by the
absence of detectable risk factors and familial clustering; individuals with family members diagnosed as affected by
AATD (family screening);Table 1 Stratification of subjects investigated as a
function of genotypic class.
Genotype N %
PI*MM 1326 62.4
PI*MS 140 6.6
PI*MZ 381 17.9
PI*MR 53 2.5
PI*SS 1 0.05
PI*SZ 39 1.8
PI*ZZ 155 7.3miscellanea (ANCA-associated vasculitis, necrotizing
panniculitis, casual detection of reduced plasma levels
of AAT).
As a result of disseminated screening programmes, large
cohorts of AATD individuals have been identified during the
last decade. As an example, the Alpha One International
Registry recently reported the largest series of AATD
individuals, detected and enrolled according to a perspec-
tive model since 1999.5 Besides the identification of subjects
presenting with severe AATD, which is understandably the
major output of the detection programmes, there are even
larger cohorts of individuals theoretically at risk investi-
gated and resulting as carriers of intermediate AATD
deficiency (PI*MZ or PI*MS) or without deficiency variants.
With the exception of subjects with intermediate AATD
detected during a family screening, only little attention, if
any, has been paid so far to the clinical characteristics of
these subjects. In the present paper we describe the
secondary outcomes of a programme aimed at detecting
individuals affected by severe AATD. Although the pro-
gramme was successfully designed for this aim, as elsewhere
reported,6,7 we nevertheless feel that it reveals other
relevant issues worth reporting and discussing.
Methods
The organisation, structure, and flow of samples and
questionnaires for diagnosis of AAT status have been already
described in detail.6 Briefly, paper filters and questionnaires
were distributed mostly among general practitioners, inter-
nal medicine physicians, and pulmonologists nationwide
since 1996. Until 2002, laboratory diagnosis for AAT status
was performed on dried blood spots (DBS) from filters by
means of immunodiffusion, to determine the AAT level, and
isoelectric focusing (IEF).6 Subsequently, genotyping and
nephelometric determination of AAT levels were intro-
duced.8,9
Based on data retrieved from the questionnaires, diag-
nosed subjects were assigned to one of the following
‘‘reason for diagnosis’’ categories (see the Introduction for
details):PI*RR 32 1.5
Total 2127 lung disease,
 liver disease, family screening,
 miscellanea.Variables (age, gender, smoking habit, pre-bronchodilator
FEV1 and FVC) were retrieved from the questionnaires, and
COPD patients were classified according to revised GOLD
parameters.10 Statistical analysis was performed with
STATISTICA for Windows (StatSoft, Bedford, UK, 2002).
Comparison between means were performed with analysis
of variance, using the Scheffe` test for post hoc comparison.
Association between category variables were compared with
Fisher’s exact test.Results
In a period spanning 11 years (1996–2006), 534 Italian
physicians contributed to our AATD detection programme,
by shipping at least one sample. A total of 2127 samples
(paper filter and questionnaire) were received and pro-
cessed. The initial stratification, reported in Table 1, was
performed according to the resulting genotype. Clinical
characteristics of individuals with the severe AATD PI*ZZ and
PI*SZ are described elsewhere6 as well as those carrying the
severe AATD PI*RR and the intermediate AATD PI*MR7; thus,
these subjects (N ¼ 279) are not included in this paper. We
did not includ also the unique PI*SS patient.
Next, remaining individuals were stratified according to
the reason for screening as detailed by the physicians
providing the sample. From this analysis, we excluded 336
subjects because of missing information regarding the
reason for screening. The large majority of samples
belonged to individuals diagnosed with pulmonary disease
(62%) followed by samples collected for family screening
(29%). In 9% of samples (145 out of 1511), patients had been
diagnosed with liver disease or other pathologies. Never-
theless, for the purposes of this paper, we further evaluated
only subjects with complete questionnaires: 508 out of 933
samples submitted for pulmonary disease and 141 out of 433
samples submitted for family screening. Moreover, among
patients diagnosed with pulmonary disease, a further 61
subjects, after careful review of questionnaires, were
excluded, since the proposed diagnosed disagreed with
normal lung function and absence of symptoms (cough and
phlegm), as reported by physicians themselves (Table 2).
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Table 2 Subjects stratified as a function of ‘‘reason for screening’’ for each genotypic class.
Reasons for
screening
Total samples PI*MM PI*MS PI*MZ
Submitted
N (%)
Evaluated Submitted
N (%)
Evaluated Submitted
N (%)
Evaluated Submitted
N (%)
Evaluated
Lung disease 933 (62) 447 586 (73) 349 66 (68) 36 98 (29) 62
Family
screening
433 (29) 141 142 (18) 50 22 (23) 5 206 (61) 86
Liver disease 67 (4) 25 (3) 4 (4) 22 (6)
Miscellanea 78 (5) 45 (6) 5 (5) 14 (4)
Table 3 Clinical characteristics of subjects diagnosed
with lung disease.
PI*MM
(N ¼ 349)
Intermediate
(PI*MS+PI*MZ)
AATD (N ¼ 98)
Male (%) 274 (78.5) 67 (68.4)
Age (years, mean) 49 52
smokers
(current+former, %)
240, 68.8 70, 71.4
FEV1 (% pred.,
mean7SD)
66.3730.2 76.6729.2
FEV1/FVC
(mean7SD)
0.7870.22 0.8370.19
AAT (mg/dL,
mean7SD)
130.5737.4 96.9727.6
p ¼ 0.009.
po0.001.
I. Ferrarotti et al.356For further analysis, and to increase the sample size, we
merged PI*MS and PI*MZ individuals in the ‘‘intermediate
AATD’’ category. We are aware that the risk for COPD varies
between PI*MS and PI*MZ subjects, since the latter genotype
is at a higher risk than the former.11,12 Nevertheless, since
the pooled (PI*MZ+PI*MS) plasma AAT level was significantly
lower (96.9727.6mg/dL, po0.001) than that of PI*MM
individuals (130.5737.4mg/dL), we decided to consider the
subjects with intermediate AATD as a single category. This
agrees with the evidence that the risk for COPD is negatively
correlated with plasma AAT level.7
The clinical characteristics of subjects diagnosed with
lung disease are described in Table 3, whereas the
stratification of the subjects according to GOLD criteria10
is reported in Table 4. Finally, the characteristics of subjects
investigated for the purpose of building a pedigree are
summarised in Table 5.Discussion
Although the programme concerns a rare condition, AATD, it
was highly successful, as testified by the 534 physicians who
shipped at least one sample for diagnosis. Nevertheless,
compliance regarding the completeness in filling in thequestionnaire that physicians were asked to ship back with
the sample was disappointing. Forty-five percent of ques-
tionnaires submitted for lung disease and even 67% of those
submitted for family screening could not be used for the
purposes of this paper because of missing information.
We observed that physicians taking part in the programme
were compliant with the guidelines to investigate subjects
at risk for AATD,4 although more than 50% of samples
submitted for lung disease actually belonged to non-
obstructed subjects. This aspect, however, cannot be
considered as a negative one as discussed below.
The large majority of subjects (62%) carried the normal
PI*MM genotype followed by those carrying the intermediate
AATD genotype PI*MZ (17.9%) (Table 1).
Regarding clinical characteristics of subjects diagnosed
with lung disease (Table 3), the PI*MM individuals and the
intermediate group did not differ substantially in terms of
gender prevalence, mean age, smoking habit, and FEV1%
predicted. The only significant difference, besides plasma
AAT levels, was that subjects with intermediate AAT
deficiency showed a slightly better (p ¼ 0.009) FEV1/FVC
than PI*MM subjects. The mean age of both groups was 49
and 52 years, respectively (early onset COPD), and in both
groups about 30% of subjects claimed that they never
smoked (absence of detectable risk factors). Lack of a
significant difference between the two groups brings to light
an intriguing observation. In fact, subjects with lung disease
carrying intermediate AATD can be considered a homoge-
neous group of subjects with common chronic lung disease
and/or symptoms in which the supposed genetic component
has been identified in the carriage of the AATalleles Z or S.13
Thus, the large group of individuals carrying the PI*MM
genotype investigated for lung disease share with the
intermediate AATD group, a relatively young age and a high
proportion never smoked. In other words, this could be a
group of individuals in which genetic susceptibility to
cigarette smoke or other environmental factors is amplified.
Individuals with such characteristics would represent an
ideal cohort for investigating susceptibility genes other than
the AAT gene14,15; their relatively young age also implies the
likelihood of finding living parents, which is an usual barrier
in designing genetic investigations in older COPD individuals.
More interesting was the stratification of the subjects
according to GOLD criteria.10 In both PI*MM and intermedi-
ate AATD, 50% and 59%, respectively, of the subjects
belonged to the at risk stage 0. The two most severe GOLD
stages (3 and 4) comprised 33% and 24% of the total
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Table 4 Stratification of subjects screened for lung disease according to GOLD classification and corresponding plasma AAT
levels.
PI*MM Intermediate deficiency (PI*MS+PI*MZ)
N (%) Plasma AAT (mg/dL, mean+SD) N (%) Plasma AAT (mg/dL, mean+SD)
Stage 0 175 (50) 130.1734.0 58 (59) 91.2725.4
Stage 1 9 (2.5) 115.1741.9 5 (5) 113.7717.4
Stage 2 49 (14) 132.5738.4 11 (11) 91.8724.7
Stage 3 61 (17.5) 128.0732.4 17 (17) 106.1731.6
Stage 4 55 (16) 135.1742.1 7 (7) 118.7728.8
Stage 1-4 174 130.9738.1 40 105.2728.9
All the other comparisons are not significant.
po0.000001 vs MM.
p ¼ 0.04 vs MM.
Table 5 Clinical phenotype of subjects investigated for family screening.
PI*MM Intermediate AATD (PI*MS+PI*MZ)
Healthy 37/50
(74%)
Lung disease 13/50
(26%)
Healthy 75/91
(82%)
Lung disease 16/91
(18%)
Male (%) 46 46 36 50
Age (years, mean) 38 38 32 37
Smokers (current+former, %) 28 65 37 43
FEV1 (% pred., mean7SD) 113.2715.4 92726.2 113713.2 99719.7
FEV1/FVC (mean7SD) 1.0170.06 0.8970.15 1.0270.07 0.9270.12
AAT (mg/dL, mean7SD) 138738 145721 94721 101725
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subsets of subjects were non-obstructed subjects with
chronic bronchitis symptoms (cough and phlegm), this
category, also referred to as stage 0, is no longer included
as a COPD stage,16 since the risk of progression towards
airflow obstruction is not clearly defined. Nevertheless, the
GOLD document emphasises the fact that the public health
message about this abnormal condition is unchanged. We
believe that a secondary, yet important output, of a
targeted detection programme for AATD is the enrolment
of subjects potentially at risk for developing COPD or in its
very early stages. Several aspects of the programme,
including information collection, blood sampling, and
reporting of the genetic analysis results, are useful to
reinforce the need for smoking cessation and other
preventive tools in subjects, irrespective of their genotype,
with a high likelihood of succeeding in changing the natural
history of their lung health if they modify their lifestyle.
An interesting feature was observed when the plasma AAT
levels were considered according to this stratification. When
the mean level of AAT in subjects with intermediate AATD in
stage 0 and the obstructed type (stage 1-4) was compared
with that of the parallel groups of PI*MM subjects, the level
of significance dropped from o0.000001 to 0.04. Our data
show that non-obstructed subjects with intermediate AATD
have plasma levels of AAT lower than that of pooled
obstructed patients. One possible explanation for thisbehaviour is that AAT is a well-known acute phase
reactant.17 In this setting, we may postulate that the
increased AAT plasma concentration would be correlated
with the systemic inflammation which is present in COPD.
This observation also correlates with the elevated C reactive
protein (CRP) in COPD subjects.18,19 An intrinsic considera-
tion for AATD diagnosis lies in the fact that the plasma level
of AAT is usually the first, crucial parameter evaluated, upon
this value further diagnostic procedures are then decided. It
would be important to carefully design the confidence
intervals for each genotypic class, in order not to mis-
diagnose subjects with intermediate AATD. These data need
confirmation and further investigation in larger cohorts.
A final consideration is reserved for subjects investigated
for family screening purposes (Table 5). As expected, in both
PI*MM and intermediate AATD groups, the majority of
individuals (74% and 82%, respectively) were healthy,
especially if they did not smoke.4 Nevertheless, PI*MZ
individuals detected by family screening should be carefully
monitored, since it has been reported that, at variance with
PI*MZ individuals detected on the basis of respiratory
symptoms, they are the only group at risk for hospital
admission for COPD.20
In conclusion, programmes for targeted detection of
AATD, such as the one currently available in Italy, yield
secondary outputs that should not be disregarded. First of
all, they confirm the importance of the important public
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directed at young individuals in very early stages of
obstructive disease. These subjects are likely to change
the natural history of their lung health if they change their
lifestyle. A second point of interest is the possibility of
enrolling smokers in whom susceptibility to environmental
factors for COPD is particularly marked. They would
represent cohorts of ideal individuals for genetic investiga-
tion. Finally, we noticed an interesting trend in plasma level
of AAT in obstructed subjects with intermediate AATD
different from that in non-obstructed cases; these findings
have prompted further investigations.
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